Overexpression of pMXs-OCT4 in Hep3B cells. (B) Cell proliferation assay of control pMXs-EGFP and pMXs-OCT4 Hep3B for 24, 48, and 72 h. (C) The secondary sphere formation percentage of control pMXs-EGFP and pMXs-OCT4 Hep3B under non-adhesion assay. Bar = 100 um. (D) Transwell assay of control pMXs-EGFP and pMXs-OCT4 Hep3B. Bar = 100 um. (E) The expression levels of migration-related protein N-cadherin and Slug in control pMXs-EGFP and pMXs-OCT4 Hep3B. (F) The cell viability of control pMXs-EGFP and pMXs-OCT4 Hep3B cells after treatment with cisplatin (0, 1, 2.5, 5, and 10 μM), bleomycin (0, 2.5, 5, 10, and 25 ug/mL), or doxorubicin (0, 0.25, 0.5, and 1 uM). *P < .05, **P < .01, by t-test.